Abstract
Introduction: Renal dysfunction at presentation is uncommon in primary membranous nephropathy (PMN). The data on the outcome of PMN patients with renal dysfunction at outset are scarce. The objective of the current study was to report the clinical outcomes of PMN patients with renal dysfunction. Material and Methods: This prospective longitudinal observational study included PMN patients (both incident and treatment resistant) with an estimated glomerular filtration rate of <60 mL/min/1.73 m2. Immunosuppressive treatment was as per the unit’s protocol. Patients were evaluated for proteinuria, creatinine, and serum albumin at monthly intervals for 6 months, then quarterly for a year, and then biannually. Both serum and tissue anti-PLA2R were performed at baseline. Outcome: Percentage of patients achieving clinical remission. Results: Sixty-four adults met study criteria and were analysed. The median (IQR) age of the patients was 48 (40, 56) years. PMN was PLA2R related in 52 (81.3%) patients. Twenty-eight (43.8%) and 30 (46.9%) patients were in remission at 12 months and at the end of the study [median (IQR) follow up: 24 months (12, 35)], respectively. Eight (12.5%) had progressed to end-stage renal disease at the last follow-up. Median (IQR) baseline anti-PLA2R titre was 150.1 RU/mL (38.5, 308). Nineteen (61.3%) and 18 (58.1%) patients with >90% reduction in anti-PLA2R titres at 12 months were in clinical remission at 12 months and at the end of the follow-up, respectively. Both cyclical cyclophosphamide/steroids (cCYC/GC) and rituximab were equally effective in inducing remission, but rituximab had a favourable adverse event profile compared to cCYC/GC. Conclusion: To conclude, both cCYC/GC and rituximab are equally effective in inducing remission of nephrotic state with compromised renal function due to PMN. Immunosuppression induces remission in up to 50% PMN patients with CKD-stage 3–4.
References
1.
Rathi
M
, Bhagat
RL
, Mukhopadhyay
P
, Kohli
HS
, Jha
V
, Gupta
KL
, Changing histologic spectrum of adult nephrotic syndrome over five decades in north India: a single center experience
. Indian J Nephrol
. 2014
;24
(2
):86
–91
.2.
Zhou
FD
, Zhao
MH
, Zou
WZ
, Liu
G
, Wang
H
. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre
. Nephrol Dial Transpl
. 2009
;24
(3
):870
–6
. .3.
Couser
WG
. Primary membranous nephropathy
. Clin J Am Soc Nephrol
. 2017
;12
(6
):983
–97
. .4.
Ponticelli
C
, Zucchelli
P
, Passerini
P
, Cesana
B
, Locatelli
F
, Pasquali
S
, A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy
. Kidney Int
. 1995
;48
(5
):1600
–4
. .5.
Jha
V
, Ganguli
A
, Saha
TK
, Kohli
HS
, Sud
K
, Gupta
KL
, A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy
. J Am Soc Nephrol
. 2007
;18
(6
):1899
–904
. .6.
Floege
J
, Barbour
SJ
, Cattran
DC
, Hogan
JJ
, Nachman
PH
, Tang
SCW
, Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference
. Kidney Int
. 2019
;95
(2
):268
–80
. .7.
Marx
BE
, Marx
M
. Prediction in idiopathic membranous nephropathy
. Kidney Int
. 1999
;56
(2
):666
–73
. .8.
Reichert
LJ
, Koene
RA
, Wetzels
JF
. Prognostic factors in idiopathic membranous nephropathy
. Am J Kidney Dis
. 1998
;31
(1
):1
–11
. .9.
Branten
AJ
, Reichert
LJ
, Koene
RA
, Wetzels
JF
. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency
. QJM
. 1998
;91
(5
):359
–66
. .10.
Howman
A
, Chapman
TL
, Langdon
MM
, Ferguson
C
, Adu
D
, Feehally
J
, Immunosuppression forprogressive membranous nephropathy: a UK randomised controlled trial
. Lancet
. 2013
;381
(9868
):744
–51
.11.
Fervenza
FC
, Appel
GB
, Barbour
SJ
, Rovin
BH
, Lafayette
RA
, Aslam
N
, Rituximab or cyclosporine in the treatment of membranous nephropathy
. N Engl J Med
. 2019
;381
(1
):36
–46
. .12.
Hanset
N
, Esteve
E
, Plaisier
E
, Johanet
C
, Michel
PA
, Boffa
JJ
, Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD
. Kidney Int Rep
. 2019
;5
(3
):331
–8
. .13.
Beck
LH
Jr, Bonegio
RG
, Lambeau
G
, Beck
DM
, Powell
DW
, Cummins
TD
, M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy
. N Engl J Med
. 2009
;361
(1
):11
–21
. .14.
Ramachandran
R
, Kumar
V
, Kumar
A
, Yadav
AK
, Nada
R
, Kumar
H
, PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians
. Nephrol Dial Transpl
. 2016
;31
(9
):1486
–93
. .15.
Van de Logt
AE
, Fresquet
M
, Wetzels
JF
, Brenchley
P
. The anti-PLA2R antibodyin membranous nephropathy: what we know and what remains a decade after itsdiscovery
. Kidney Int
. 2019
;96
(6
):1292
–302
.16.
Sethi
S
, Haas
M
, Markowitz
GS
, D’Agati
VD
, Rennke
HG
, Jennette
JC
, Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN
. J Am Soc Nephrol
. 2016
;27
(5
):1278
–87
. .17.
Astor
BC
, Matsushita
K
, Gansevoort
RT
, van der Velde
M
, Woodward
M
, Levey
AS
, Lowerestimated glomerular filtration rate and higher albuminuria are associated withmortality and end-stage renal disease. A collaborative meta-analysis of kidneydisease population cohorts
. Kidney Int
. 2011
;79
(12
):1331
–40
.18.
Mathieson
PW
, Turner
AN
, Maidment
CG
, Evans
DJ
, Rees
AJ
. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function
. Lancet
. 1988
;2
(8616
):869
–72
. .19.
Jindal
K
, West
M
, Bear
R
, Goldstein
M
. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function
. Am J Kidney Dis
. 1992
;19
(1
):61
–7
. .20.
Cattran
DC
, Greenwood
C
, Ritchie
S
, Bernstein
K
, Churchill
DN
, Clark
WF
, A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian glomerulonephritis Study Group
. Kidney Int
. 1995
;47
(4
):1130
–5
. .21.
du Buf-Vereijken
PW
, Branten
AJ
, Wetzels
JF
. Membranous nephropathy StudyGroup. cytotoxic therapy for membranous nephropathy and renal insufficiency:improved renal survival but high relapse rate
. Nephrol Dial Transpl
. 2004
;19
(5
):1142
–8
.22.
Ramachandran
R
, Yadav
AK
, Kumar
V
, Siva Tez Pinnamaneni
V
, Nada
R
, Ghosh
R
, Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide
. Kidney Int Rep
. 2017 Jul
;2
(4
):610
–6
. .23.
Dahan
K
, Debiec
H
, Plaisier
E
, Cachanado
M
, Rousseau
A
, Wakselman
L
, Rituximab for severe membranous nephropathy: a 6-month trial with extendedfollow-up
. J Am Soc Nephrol
. 2017
;28
(1
):348
–58
.24.
Qiu
TT
, Zhang
C
, Zhao
HW
, Zhou
JW
. Calcineurin inhibitors versuscyclophosphamide for idiopathic membranous nephropathy: a systematic review andmeta-analysis of 21 clinical trials
. Autoimmun Rev
. 2017
;16
(2
):136
–45
.25.
Ramachandran
R
, Bharati
J
, Rao
I
, Kashif
AW
, Nada
R
, Minz
R
, Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy
. Nephrology
. 2019
;24
(12
):1241
–7
. .26.
Barbour
S
, Lo
C
, Espino-Hernandez
G
, Sajjadi
S
, Feehally
J
, Klarenbach
S
, The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice
. Nephrol Dial Transpl
. 2018
;33
(4
):626
–34
. .27.
Tse
KC
, Tang
CS
, Lam
MF
, Yap
DY
, Chan
TM
. Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis
. J Rheumatol
. 2009
;36
(1
):76
–81
. .28.
Hoxha
E
, Thiele
I
, Zahner
G
, Panzer
U
, Harendza
S
, Stahl
RA
. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy
. J Am Soc Nephrol
. 2014
;25
(6
):1357
–66
. .29.
Pourcine
F
, Dahan
K
, Mihout
F
, Cachanado
M
, Brocheriou
I
, Debiec
H
, Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2Rantibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years
. PLoS One
. 2017
;12
(3
):e0173201
.30.
De Vriese
AS
, Glassock
RJ
, Nath
KA
, Sethi
S
, Fervenza
FC
. A proposal for a serology-based approach to membranous nephropathy
. J Am Soc Nephrol
. 2017
;28
(2
):421
–30
. .31.
Mahmud
M
, Pinnschmidt
HO
, Reinhard
L
, Harendza
S
, Wiech
T
, Stahl
RAK
, Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy
. PLoS One
. 2019
;14
(9
):e0221293
. .32.
Van den Brand
JAJG
, Ruggenenti
P
, Chianca
A
, Hofstra
JM
, Perna
A
, Ruggiero
B
, Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy
. J Am Soc Nephrol
. 2017
;28
(9
):2729
–37
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
